RxDoctor Payments Data

Courtney Ramsey

Family · Moberly, MONPI 1528450079

Payments from drug & device makers

$4,308in general payments, 2019–2025

Across 268 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$712
  • Novo Nordisk$690
  • AbbVie$662
  • Lilly USA, LLC$459
  • Amgen$236
  • Takeda Pharmaceuticals U.S.A., Inc.$177
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$4,308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,308 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$73,716
TrulicityDulaglutide44$52,270
FarxigaDapagliflozin Propanediol50$39,162
LinzessLinaclotide37$22,872
VraylarCariprazine Hcl13$18,501
Repatha SureclickEvolocumab22$14,949
Tresiba Flextouch U-200Insulin Degludec11$6,601
SymbicortBudesonide/Formoterol Fumarate24$5,794
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,313
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,189
Insulin Lispro Kwikpen U-100Insulin Lispro12$2,150
Pregabalin71$2,136
Humalog Kwikpen U-100Insulin Lispro12$1,660
Omeprazole110$1,470
Atorvastatin Calcium218$1,269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$690$73,71662 claims
Lilly USA, LLCTrulicity$459$52,27044 claims
AstraZenecaFarxiga, Symbicort$712$44,95674 claims
AbbVieLinzess, Vraylar$662$41,37350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Moberly

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →